Posted by Michael Wonder on 22 Jan 2018
European Commission approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for treatment of paediatric patients 12 years and older with unresectable or metastatic melanoma
22 January 2018 - Yervoy is the first and only immuno-oncology agent to receive approval in the European Union in this patient population.
Bristol-Myers Squibb announced today that the European Commission has expanded the indication of Yervoy (ipilimumab) to include treatment of advanced (unresectable or metastatic) melanoma in paediatric patients 12 years of age and older.
Yervoy has been evaluated in paediatric and adolescent patient populations across two clinical trials: a dose-finding study in 33 patients aged two to 21 years with relapsed or refractory solid tumours; and an open-label, single-arm trial in 12 adolescents (ages ranging from 12 to 16 years) with previously treated or untreated, unresectable Stage III or IV malignant melanoma.
